AQST
VENTE TOTALE: 25 000 titres (~107 167,50 $ US)
- Insiders
- Barber Daniel
- Total bought
- —
- Total sold
- $107,168
- Last activity
- 2026-08-17
- Last synced
-
2026-08-23 00:12:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
AQST presents a deeply unfavorable risk/reward profile: catastrophic fundamentals (-188% net margin, negative interest coverage, rapid cash burn) overwhelm a modest earnings catalyst with mixed signals (revenue beat but…
The first sentence of the analysis written for AQST on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.5% | 69.0% | 58.8% | 59.3% | 70.5% | |
| Ebit Margin | -149.7% | -47.5% | -0.3% | -88.0% | -94.6% | |
| Ebitda Margin | -148.4% | -46.2% | 2.3% | -83.0% | -88.8% | |
| Operating Profit Margin | -156.4% | -53.5% | -29.9% | -88.2% | -68.2% | |
| Pretax Profit Margin | -188.1% | -76.7% | -15.1% | -114.1% | -138.8% | |
| Continuous Operations Profit Margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | |
| Net Profit Margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | |
| Bottom Line Profit Margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | |
| Current Ratio | 3.135 | 4.676 | 2.238 | 1.009 | 2.152 | |
| Quick Ratio | 3.006 | 4.356 | 1.868 | 0.863 | 1.968 | |
| Solvency Ratio | -0.429 | -0.269 | -0.040 | -0.296 | -0.469 | |
| Cash Ratio | 2.545 | 3.793 | 1.304 | 0.690 | 1.276 | |
| Price To Earnings Ratio | -8.500 | -6.980 | -15.538 | -0.805 | -2.103 | |
| Price To Earnings Growth Ratio | -0.173 | -0.024 | 0.176 | 0.020 | -0.184 | |
| Forward Price To Earnings Growth Ratio | -0.173 | -0.024 | 0.176 | 0.020 | -0.184 | |
| Price To Earnings Diluted Ratio | -8.500 | -6.980 | -15.538 | -0.805 | -2.103 | |
| Price To Earnings Diluted Growth Ratio | -0.173 | -0.024 | 0.176 | 0.020 | -0.184 | |
| Price To Book Ratio | -23.406 | -5.132 | -1.162 | -0.371 | -1.803 | |
| Price To Sales Ratio | 17.688 | 5.364 | 2.446 | 0.922 | 2.914 | |
| Price To Free Cash Flow Ratio | -14.868 | -8.596 | -16.778 | -3.570 | -4.370 | |
| Price To Operating Cash Flow Ratio | -15.027 | -8.634 | -19.394 | -4.491 | -4.491 | |
| Debt To Assets Ratio | 0.819 | 0.375 | 0.580 | 1.007 | 0.910 | |
| Debt To Equity Ratio | -3.905 | -0.632 | -0.313 | -0.485 | -0.687 | |
| Debt To Capital Ratio | 1.344 | -1.716 | -0.455 | -0.941 | -2.194 | |
| Long Term Debt To Capital Ratio | 1.411 | -1.175 | -0.348 | -0.393 | -1.686 | |
| Financial Leverage Ratio | -4.766 | -1.686 | -0.539 | -0.481 | -0.755 | |
| Working Capital Turnover Ratio | 0.521 | 1.251 | 4.395 | 3.717 | 2.083 | |
| Operating Cash Flow Ratio | -1.101 | -1.896 | -0.348 | -0.248 | -1.502 | |
| Operating Cash Flow Sales Ratio | -1.177 | -0.621 | -0.126 | -0.205 | -0.649 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.011 | 1.004 | 1.156 | 1.258 | 1.028 | |
| Debt Service Coverage Ratio | -2.302 | -1.579 | 0.125 | -1.271 | -1.842 | |
| Interest Coverage Ratio | -4.073 | -1.830 | -2.024 | -3.381 | -1.544 | |
| Short Term Operating Cash Flow Coverage Ratio | -4.510 | -1,375.346 | -290.000 | -0.523 | -16.286 | |
| Operating Cash Flow Coverage Ratio | -0.399 | -0.941 | -0.191 | -0.170 | -0.585 | |
| Capital Expenditure Coverage Ratio | -93.295 | -224.899 | -6.412 | -3.878 | -36.122 | |
| Dividend Paid And Capex Coverage Ratio | -93.295 | -224.899 | -6.412 | -3.878 | -36.122 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.071 | -10.340 | 112.677 | -1.874 | -3.913 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.5% | ▼-7.5% | ▼-2.3% |
| Ebit Margin | -149.7% | ▼-102.2% | ▼-73.7% |
| Ebitda Margin | -148.4% | ▼-102.2% | ▼-75.6% |
| Operating Profit Margin | -156.4% | ▼-102.9% | ▼-77.1% |
| Pretax Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Continuous Operations Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Net Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Bottom Line Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Current Ratio | 3.135 | ▼-1.541 | ▲0.493 |
| Quick Ratio | 3.006 | ▼-1.350 | ▲0.594 |
| Solvency Ratio | -0.429 | ▼-0.160 | ▼-0.128 |
| Cash Ratio | 2.545 | ▼-1.247 | ▲0.624 |
| Price To Earnings Ratio | -8.500 | ▼-1.520 | ▼-1.715 |
| Price To Earnings Growth Ratio | -0.173 | ▼-0.149 | ▼-0.136 |
| Forward Price To Earnings Growth Ratio | -0.173 | ▼-0.149 | ▼-0.136 |
| Price To Earnings Diluted Ratio | -8.500 | ▼-1.520 | ▼-1.715 |
| Price To Earnings Diluted Growth Ratio | -0.173 | ▼-0.149 | ▼-0.136 |
| Price To Book Ratio | -23.406 | ▼-18.274 | ▼-17.031 |
| Price To Sales Ratio | 17.688 | ▲12.324 | ▲11.821 |
| Price To Free Cash Flow Ratio | -14.868 | ▼-6.272 | ▼-5.231 |
| Price To Operating Cash Flow Ratio | -15.027 | ▼-6.393 | ▼-4.620 |
| Debt To Assets Ratio | 0.819 | ▲0.445 | ▲0.081 |
| Debt To Equity Ratio | -3.905 | ▼-3.273 | ▼-2.701 |
| Debt To Capital Ratio | 1.344 | ▲3.060 | ▲2.137 |
| Long Term Debt To Capital Ratio | 1.411 | ▲2.587 | ▲1.849 |
| Financial Leverage Ratio | -4.766 | ▼-3.080 | ▼-3.120 |
| Working Capital Turnover Ratio | 0.521 | ▼-0.730 | ▼-1.872 |
| Operating Cash Flow Ratio | -1.101 | ▲0.794 | ▼-0.082 |
| Operating Cash Flow Sales Ratio | -1.177 | ▼-0.556 | ▼-0.621 |
| Free Cash Flow Operating Cash Flow Ratio | 1.011 | ▲0.006 | ▼-0.081 |
| Debt Service Coverage Ratio | -2.302 | ▼-0.723 | ▼-0.928 |
| Interest Coverage Ratio | -4.073 | ▼-2.243 | ▼-1.503 |
| Short Term Operating Cash Flow Coverage Ratio | -4.510 | ▲1370.836 | ▲332.823 |
| Operating Cash Flow Coverage Ratio | -0.399 | ▲0.542 | ▲0.058 |
| Capital Expenditure Coverage Ratio | -93.295 | ▲131.604 | ▼-20.374 |
| Dividend Paid And Capex Coverage Ratio | -93.295 | ▲131.604 | ▼-20.374 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.071 | ▼-1.731 | ▼-28.967 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $787.9M | $308.7M | $123.7M | $44.0M | $148.1M | |
| Enterprise value | $798.2M | $275.2M | $133.2M | $74.2M | $176.5M | |
| EV / Sales | 17.92x | 4.78x | 2.63x | 1.56x | 3.47x | |
| EV / Op. cash flow | -15.22x | -7.70x | -20.88x | -7.58x | -5.35x | |
| EV / Free cash flow | -15.06x | -7.66x | -18.06x | -6.02x | -5.21x | |
| EV / EBITDA | -12.07x | -10.34x | 112.68x | -1.87x | -3.91x | |
| Net debt / EBITDA | -0.15x | 1.26x | 7.99x | -0.76x | -0.63x | |
| Current ratio | 3.13x | 4.68x | 2.24x | 1.01x | 2.15x | |
| Income quality | 0.63x | 0.81x | 0.81x | 0.18x | 0.47x | |
| Graham net-net | -$0 | -$1 | -$2 | -$3 | -$3 | |
| Tax burden | 100.0% | 100.0% | 103.2% | 100.0% | 100.0% | |
| Interest burden | 125.6% | 161.5% | 4677.9% | 129.6% | 146.7% | |
| Working capital | $101.7M | $69.4M | $22.7M | $360K | $25.3M | |
| Invested capital | $110.2M | $78.3M | $33.7M | $11.1M | $33.1M | |
| Return on assets | -52.2% | -43.5% | -13.7% | -95.3% | -113.8% | |
| Operating ROA | -53.2% | -38.7% | -26.4% | -70.7% | -55.5% | |
| Return on tangible assets | -52.2% | -43.5% | -14.0% | -97.8% | -113.9% | |
| Return on equity | 248.9% | 73.4% | 7.4% | 45.9% | 85.9% | |
| Return on invested capital | -56.0% | -37.0% | -38.2% | -115.3% | -80.7% | |
| Return on capital employed | -61.7% | -37.3% | -38.6% | -239.8% | -86.6% | |
| Earnings yield | -10.6% | -14.3% | -6.4% | -123.8% | -47.6% | |
| Free cash flow yield | -6.7% | -11.6% | -6.0% | -28.0% | -22.9% | |
| Capex / Op. cash flow | -1.1% | -0.4% | -15.6% | -25.8% | -2.8% | |
| Capex / Depreciation | 102.6% | 22.1% | 74.0% | 105.7% | 30.8% | |
| Capex / Sales | 1.3% | 0.3% | 2.0% | 5.3% | 1.8% | |
| SG&A / Sales | 179.3% | 87.2% | 62.8% | 110.9% | 105.2% | |
| R&D / Sales | 38.6% | 35.2% | 25.9% | 36.7% | 33.5% | |
| Stock comp / Sales | 17.1% | 12.3% | 5.3% | 9.2% | 13.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 2.2% | 2.5% | 0.1% | |
| Days sales outstanding | 146d | 47d | 61d | 36d | 87d | |
| Days payables outstanding | 635d | 210d | 156d | 187d | 202d | |
| Operating cycle | 277d | 170d | 180d | 145d | 185d | |
| Cash conversion cycle | -359d | -40d | 23d | -42d | -17d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+155.2%EV / Sales ▲+274.8%EV / EBITDA ▼-16.7%EV / Op. cash flow ▼-7.527Earnings yield ▲+0.037
Profitability
Return on equity ▲+1.755Return on assets ▼-0.087Return on invested capital ▼-0.190Return on capital employed ▼-0.245Operating ROA ▼-0.145Income quality ▼-0.184Tax burden +0.000
Efficiency
Days sales outstanding ▲+98.980Days payables outstanding ▲+425.297Operating cycle ▲+106.804Cash conversion cycle ▼-318.492Capex / Sales ▲+0.010R&D / Sales ▲+0.034
Balance-sheet strength
Current ratio ▼-1.541Net debt / EBITDA ▼-1.416Working capital ▲+32306000.000Invested capital ▲+31839000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+431.9%EV / Sales ▲+416.0%EV / EBITDA ▼-208.5%EV / Op. cash flow ▼-9.871Earnings yield ▲+0.370
Profitability
Return on equity ▲+1.630Return on assets ▲+0.616Return on invested capital ▲+0.248Return on capital employed ▲+0.249Operating ROA ▲+0.023Income quality ▲+0.158Tax burden 0.000
Efficiency
Days sales outstanding ▲+58.521Days payables outstanding ▲+432.933Operating cycle ▲+91.452Cash conversion cycle ▼-341.480Capex / Sales ▼-0.005R&D / Sales ▲+0.051
Balance-sheet strength
Current ratio ▲+0.984Net debt / EBITDA ▲+0.474Working capital ▲+76366000.000Invested capital ▲+77049000.000Intangibles / Total assets ▼-0.001
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-12 Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
- 2026-08-12 Aquestive Therapeutics Q2 Earnings Call Highlights Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Administration.
- 2026-08-11 Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
- 2026-08-11 Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2026, and provided a strategic business update.
- 2026-08-10 Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film.
- 2026-08-10 Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026 Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK results Revised packaging design reduced median time to open pouch from 17 seconds in the previous human factors study to 3 seconds Revised instructions for use reduced incorrect film placement from previous human factors validation study by over 80% Top-of-tongue PK arm showed clinically meaningful pharmacodynamic (PD) results WARREN, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, today announced results from its human factors (HF) validation study and pharmacokinetic (PK) study for Anaphylm™ (dibutepinephrine) sublingual film, conducted in support of the Company''s planned resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of Type 1 allergic reactions, including anaphylaxis.
- 2026-07-29 Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2026, and provide an update on recent developments in its business after market close on Tuesday, August 11, 2026.
- 2026-07-07 Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host 1x1 investor meetings on July 14, 2026.
- 2026-06-24 Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.